GTxGTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting, and other serious medical conditions.

GTx successfully completed an IPO in February 2004.  We distributed our GTx shares to Fund I investors in December 2006.

Marc Hanover
GTx, Inc.
Interim CEO, President & COO